Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single Arm Study to Evaluate the Safety of Dacomitinib for the First-Line Treatment of Participants in India With Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR)-Activating Mutations

Next Previous
Trial Profile

Single Arm Study to Evaluate the Safety of Dacomitinib for the First-Line Treatment of Participants in India With Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR)-Activating Mutations

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dacomitinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Pfizer

Most Recent Events

  • 22 Dec 2022 Status changed from active, no longer recruiting to completed.
  • 20 Jan 2022 Planned End Date changed from 2 Feb 2023 to 18 Oct 2022.
  • 20 Jan 2022 Planned primary completion date changed from 2 Feb 2023 to 18 Oct 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top